We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness of Alzheimer's Universe (Www.AlzU.Org) on Knowledge and Behavior

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03149380
Recruitment Status : Recruiting
First Posted : May 11, 2017
Last Update Posted : February 1, 2022
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
To evaluate the effectiveness of an online educational course on Alzheimer's disease (AD) prevention, treatment and caregiving.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Alzheimer Disease, Late Onset Memory Loss Patient Education as Topic Behavioral: Web-based education Not Applicable

Detailed Description:
Alzheimer's Universe (www.AlzU.org) was created to provide online education about Alzheimer's disease (AD), with a focus on family members of people with AD, people with mild cognitive impairment due to AD and mild AD, caregivers, healthcare providers, medical students, college students and high school students. The website provides evidence-based courses with interactive lessons and activities that have been shown to increase knowledge about AD, willingness to participate in an AD prevention clinical trial, and intent to make specific lifestyle changes in effort to reduce AD risk.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10000 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Evaluating the Effectiveness of Web-based Education Via Alzheimer's Universe (Www.AlzU.Org) on Knowledge and Behavior: A Randomized Trial
Study Start Date : January 2017
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : October 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention
Subjects will be given access to educational content on AD using interactive learning strategies
Behavioral: Web-based education
The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.

Sham Comparator: Time-neutral control
Subjects will be given access to time-neutral general educational content on AD
Behavioral: Web-based education
The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.




Primary Outcome Measures :
  1. Knowledge of AD Preventative behaviors [ Time Frame: 12 months ]
    Knowledge is calculated as a positive change on multiple-choice questions about AD between pre vs. post-completion of educational material

  2. Willingness to Engage in AD Preventative behaviors [ Time Frame: 12 months ]
    Willingness is calculated as a positive change on questionnaires evaluating AD-preventative behaviors between pre vs. post-completion of educational material


Secondary Outcome Measures :
  1. Participant Satisfaction [ Time Frame: 12 months ]
    The investigators will assess general satisfaction with the educational modules via pre vs post-intervention participant surveys

  2. Behavioral Assessments [ Time Frame: 12 months ]
    The investigators will evaluate related behavioral assessments via pre vs post-intervention participant surveys



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • greater than or equal to 14 years old with a friend, family member or acquaintance with Alzheimer's disease or memory loss, OR a person diagnosed with mild memory loss (including mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease), OR an AD caregiver, OR healthcare providers, OR a medical student, college student or high school student.

Exclusion Criteria:

  • < 14 years old, OR diagnosis of moderate or severe Alzheimer's disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03149380


Contacts
Layout table for location contacts
Contact: Nabeel Saif, MS 2127462105 nas2782@med.cornell.edu

Locations
Layout table for location information
United States, New York
Weill Medical College of Cornell University Recruiting
New York, New York, United States, 10021
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Layout table for investigator information
Principal Investigator: Richard Isaacson, MD Weill Medical College of Cornell University
Additional Information:
Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT03149380    
Other Study ID Numbers: 1311014539
First Posted: May 11, 2017    Key Record Dates
Last Update Posted: February 1, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Memory Disorders
Late Onset Disorders
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Disease Attributes
Pathologic Processes